Research Program

Hematopoiesis and Hematological Malignancies

Program Leaders: Wendy Stock, MD, and Lucy Godley, MD, PhD

Members of this program have played a major role in the identification of many genes that are involved in normal hematopoiesis (the development of blood cells), as well as in the pathogenesis of leukemias and lymphomas over the past 30 years. The identification of genetic pathways involved in hematological malignant diseases has important implications for the diagnosis and treatment of these diseases. The Hematopoiesis and Hematological Malignancies Program comprises 30 members from three academic departments who are tightly linked by common research themes.

The Hematopoiesis and Hematological Malignancies Program seeks to:

Determine the mechanisms of normal and malignant hematopoiesis;

Define recurring molecular genetic abnormalities in leukemia and lymphoma; and

Basic and translational research efforts provide key insights for the design of novel therapies for patients with hematological diseases. Members of this program are actively translating their findings from basic research into novel, molecularly targeted therapeutic approaches for hematological malignancies.